“The Pertussis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Pertussis pipeline products will significantly revolutionize the Pertussis market dynamics”
The Pertussis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Pertussis market size from 2019 to 2032. The report also covers current Pertussis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Pertussis Market Report
- The increased number of pertussis from past few decades, along with the emerging prophylactic treatment, is likely to contribute directly to the Pertussis market growth during the forecast period.
- As per the study by Robert Koch Institute (2020), the use of the pertussis vaccination, on the other hand, has increased in recent years. While 32.7% of adults nationwide had received a pertussis vaccination within the last 10years by 2016, the vaccination rate in 2019 was already 41.9%.
- The leading Pertussis Companies are working in the market include Mitsubishi Tanabe Pharma, Sanofi, ILiAD Biotechnologies, Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others
- Promising Pertussis Pipeline Therapies in the various stages of development include DTwP-HepB-IPV-Hib, BPZE 1, and others
- In January 2022, LiAD Biotechnologies announced that the USFDA has granted Fast Track designation to BPZE1 for active booster immunization against pertussis. BPZE1: ILiAD Biotechnologies is a technologically advanced live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins that are inactivated pertussis toxin, deleted dermonecrotic toxin, and marked reduction in Tracheal toxin to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. Based on the positive topline results from ILiADBiotechnologies on the Phase IIb trial of lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress, it met both primary endpoints of overall safety and induction of mucosal immunity
Discover more about therapies set to grab major Pertussis Market Share @ Pertussis Market Size
Pertussis Overview
Pertussis, literally meaning “a violent cough,” and also known as whooping cough, or “the cough of 100 days,” was first described in the Paris epidemic of 1578. Bordetella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality.
Pertussis Epidemiology Segmentation in the 7MM
- Age-Specific Vaccination Coverage
Download the report to understand which factors are driving Pertussis Epidemiology Trends @ Pertussis Epidemiological Insights
Pertussis Emerging Drugs
- DTwP-HepB-IPV-Hib: Serum Institute of India
A hexavalent conjugate vaccine (DTwP-HepB-IPV-Hib) is being developed by Serum Institute of India, for the prevention of diphtheria, tetanus, whole-cell pertussis (DTaP), poliomyelitis and Haemophilus influenzae type B (Hib) in infants.
- BPZE 1: ILiAD Biotechnologies
BPZE1 is an investigational live-attenuated intranasal vaccine designed to induce comprehensive and durable protection against Bordetella pertussis (B. pertussis) infection and disease. By blocking B. pertussis colonization in nasal passages, the vaccine may also prevent transmission, thereby reducing the incidence of pertussis disease. The designation is supported by data from 4 clinical trials evaluating BPZE1 in healthy adults.
Pertussis Treatment Market
The prevention of pertussis centers on community vaccination. Recent immunization efforts have focused on adults because they are the primary transmitters of the disease to infants and are at risk of infection themselves. The whole-cell pertussis vaccine in combination with diphtheria and tetanus toxoids was introduced in 1948. Acellular pertussis vaccines were developed after studies raised concerns about a temporal relation between pertussis-containing vaccines and neurologic illnesses, including encephalopathy, infantile spasms, and sudden infant death syndrome. They include representative antigens of pathologic toxins seen in B. pertussis strains.
To know more about Pertussis Treatment options, visit @ Pertussis Drugs
Pertussis Market Dynamics
The Pertussis Market Dynamics is anticipated to change in the coming years owing to the improvement in the Increase in the recommendation of vaccination programs in pregnant women, raising awareness of the diseases, incremental healthcare spending across the world. The vaccine are develope by key players, such as, ILiAD Biotechnologies (BPZE1), Serum Institute of India, Bilthoven Biologicals and Vakzine Projekt Management GmbH (SIIPL Tdap), Mitsubishi Tanabe Pharma Corporation (BK1310/MT2355), that are under late – and mid-phase of clinical development have the potential to create a significant positive shift in Pertussis market size. The launch of emerging therapies is expected during the forecast period of 2023–2032.
Pertussis Market Drivers
- Increase in the recommendation of vaccination programs in pregnant women
- Increasing Awareness Programs
- Increasing population of pertussis
Pertussis Market Barriers
- Acellular vaccines less effective in the current market
- Lack of patient awareness
- Barriers to developing a new whole-cell version of pertussis vaccine
- Different vaccination policies amongst various countries
Learn more about the Pertussis Pipeline Therapies in clinical trials @ Pertussis Market Landscape
Scope of the Pertussis Market Report
- Coverage- 7MM
- Study Period- 2019-2032
- Pertussis Companies- Mitsubishi Tanabe Pharma, Sanofi (NYSE: SAN), ILiAD Biotechnologies, Serum Institute of India, LG Chem, Dynavax Technologies (NYSE: DVAX), Tianjin CanSino Biotechnology, Faron Pharmaceuticals (NYSE: FARON.HE), Kymab, BioNet and others
- Pertussis Pipeline Therapies- DTwP-HepB-IPV-Hib, BPZE 1, and others.
- Pertussis Market Dynamics: Pertussis Market Drivers and Barriers
- Pertussis Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Discover more about Pertussis Drugs in development @ Pertussis Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Pertussis Executive Summary
- Pertussis Competitive Intelligence Analysis
- Pertussis: Market Overview at a Glance
- Pertussis: Disease Background and Overview
- Patient Journey
- Pertussis Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Pertussis Unmet Needs
- Key Endpoints of Pertussis Treatment
- Pertussis Marketed Products
- Pertussis Emerging Therapies
- Pertussis: Seven Major Market Analysis
- Attribute analysis
- 7MM: Pertussis Market Outlook
- Pertussis Market Access and Reimbursement Overview
- KOL Views
- Pertussis Market Drivers
- Pertussis Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Pertussis Market Drivers and Barriers
Top Selling Market Research Reports in 2023
Bronchial Spasm Market | Meningioma Market | Necrotizing Enterocolitis Market Hyperhidrosis Market |Bacterial Meningitis Market | Anaphylaxis Market | Neurostimulation Devices Market | Intracranial Pressure Monitoring Devices Market | Acute Pharyngitis Market | Hepatitis B Virus Market | Thymic Carcinoma Market | Bladder Cancer Market | Spasticity Market | Interbody Cages Market | Helicobacter Pylori Infection Market | Intravenous Immunoglobulin Market | Opioid Induced Constipation Market | Ophthalmic Imaging Equipment Market | Epilepsy Market | Pharmaceutical Consulting Companies | Acquired Immunodeficiency Syndrome Market | Image Guided Surgery Devices Market | Androgenetic Alopecia Market | Acute Lung Injury Market | Astigmatism Market | Familial Primary Pulmonary Hypertension Market | Progressive Multifocal Leukoencephalopathy Market
Read More about Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj